Effects of propofol/remifentanil-based total intravenous anesthesia versus sevofluranebased inhalational anesthesia on the release of VEGF-C and TGF-ß and prognosis after breast cancer surgery: a prospective, randomized and controlled study

Effect of Anesthetic Technique on Angiogenesis, Immunity and Prognosis after Breast Cancer Surgery: a Prospective, Randomized and Controlled Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017910

Enrollment

Unknown

Registered

2018-08-21

Start date

2016-01-01

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

group 1:sevoflurane-based inhalational anesthesia

group 2:propofol/remifentanil-based total intravenous anesthesia (TIVA)

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: adult female patients aged 18 to 80 years, ASA physical status I and II, undergoing modified radical mastectomy(MRM) or breast conserving surgery(BCS) for confirmed breast cancer were enrolled in the study

Exclusion criteria

Exclusion criteria: Previous breast cancer surgery (except tumor biopsy); bilateral breast surgery; preoperative chemotherapy; contraindication to use of sevoflurane, propofol and nonsteroidal anti-inflammatory drugs (NSAIDs).

Design outcomes

Primary

Measure	Time frame
Vascular endothelial growth factor;	—

Secondary

Measure	Time frame
transforming growth factor-ß;Visual Analogue Scale;Disease free survival;Overall survival;	—

Countries

China

Contacts

Public ContactSUN LI

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

lisun_2008@163.com+86 13801231361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026